Eight-Year Clinical Outcomes of Long-Term Enzyme Replacement Therapy for 884 Children With Gaucher Disease Type 1

被引:113
作者
Andersson, Hans [1 ]
Kaplan, Paige [2 ]
Kacena, Katherine [3 ]
Yee, John [3 ]
机构
[1] Tulane Univ, Sch Med, Hayward Genet Ctr, New Orleans, LA 70112 USA
[2] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA
[3] Genzyme Corp, Cambridge, MA USA
关键词
Gaucher disease type 1; children; enzyme replacement therapy; growth; hemoglobin; platelet count; liver and spleen volumes; bone mineral density; alglucerase; imiglucerase;
D O I
10.1542/peds.2007-2144
中图分类号
R72 [儿科学];
学科分类号
100202 [儿科学];
摘要
OBJECTIVE. The goal was to analyze the clinical responses to enzyme replacement therapy with alglucerase or imiglucerase in a large international cohort of children with Gaucher disease type 1. METHODS. Anonymized data from 884 children in the International Collaborative Gaucher Group Gaucher Registry were analyzed to determine the effects of long-term enzyme replacement therapy with alglucerase or imiglucerase on hematologic and visceral manifestations, linear growth, and skeletal disease. The parameters measured were hemoglobin levels, platelet counts, spleen and liver volumes, z scores for height and bone mineral density, and reports of bone pain and bone crises. RESULTS. The median height z score for the study population was -1.4 at baseline. After 8 years of treatment, the median height approximated the median value for the normal population. Anemia, although not severe, was present in > 50% of patients at baseline and resolved for all patients after 8 years of treatment. More than 50% of patients had platelet counts of < 100 000 platelets per mm(3) at baseline, but > 95% had platelet counts above this level after 8 years of treatment. Liver and spleen volumes decreased over 8 years of treatment. The mean bone mineral density z score was -0.34 at baseline, and values normalized within 6.6 years of treatment. Seventeen percent of patients reported a bone crisis before treatment and in the first 2 years of treatment, but no bone crises were reported after 2 years of enzyme replacement therapy. Few patients (2.5%) without bone crises before enzyme replacement therapy had a crisis after the start of treatment. CONCLUSIONS. These longitudinal data quantitate the benefits of continuous enzyme replacement therapy with alglucerase/imiglucerase for children with Gaucher disease type 1. Within 8 years of enzyme replacement therapy, most clinical parameters studied became normal or nearly normal. Pediatrics 2008; 122: 1182-1190
引用
收藏
页码:1182 / 1190
页数:9
相关论文
共 35 条
[1]
Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease [J].
Altarescu, G ;
Schiffmann, R ;
Parker, CC ;
Moore, DF ;
Kreps, C ;
Brady, RO ;
Barton, NW .
BLOOD CELLS MOLECULES AND DISEASES, 2000, 26 (04) :285-290
[2]
Lessons learned from the development of enzyme therapy for Gaucher disease [J].
Barranger, JA ;
O'Rourke, E .
JOURNAL OF INHERITED METABOLIC DISEASE, 2001, 24 :89-96
[3]
AMINOHYDROXYPROPYLIDENE-BIPHOSPHONATE IN THE TREATMENT OF BONE-LESIONS IN A CASE OF GAUCHERS-DISEASE TYPE-3 [J].
BEMBI, B ;
AGOSTI, E ;
BOEHM, P ;
NASSIMBENI, G ;
ZANATTA, M ;
VIDONI, L .
ACTA PAEDIATRICA, 1994, 83 (01) :122-124
[4]
Beutler E., 2001, METABOLIC MOL BASES, V3, P3635
[5]
Official positions of the International Society for Clinical Densitometry and executive summary of the 2005 Position Development Conference [J].
Binkley, Neil ;
Bilezikian, John P. ;
Kendler, David L. ;
Leib, Edward S. ;
Lewiecki, E. Michael ;
Petak, Steven M. .
JOURNAL OF CLINICAL DENSITOMETRY, 2006, 9 (01) :4-14
[6]
CRITICAL YEARS AND STAGES OF PUBERTY FOR SPINAL AND FEMORAL BONE MASS ACCUMULATION DURING ADOLESCENCE [J].
BONJOUR, JP ;
THEINTZ, G ;
BUCHS, B ;
SLOSMAN, D ;
RIZZOLI, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (03) :555-563
[7]
Gaucher's disease: past, present and future [J].
Brady, RO .
BAILLIERES CLINICAL HAEMATOLOGY, 1997, 10 (04) :621-634
[8]
The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease [J].
Charrow, J. ;
Dulisse, B. ;
Grabowski, G. A. ;
Weinreb, N. J. .
CLINICAL GENETICS, 2007, 71 (03) :205-211
[9]
Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: Consensus recommendations [J].
Charrow, J ;
Andersson, HC ;
Kaplan, P ;
Kolodny, EH ;
Mistry, P ;
Pastores, G ;
Prakash-Cheng, A ;
Rosenbloom, BE ;
Scott, CR ;
Wappner, RS ;
Weinreb, NJ .
JOURNAL OF PEDIATRICS, 2004, 144 (01) :112-120
[10]
The Gaucher registry -: Demographics and disease characteristics of 1698 patients with Gaucher disease [J].
Charrow, J ;
Andersson, HC ;
Kaplan, P ;
Kolodny, EH ;
Mistry, P ;
Pastores, G ;
Rosenbloom, BE ;
Scott, CR ;
Wappner, RS ;
Weinreb, NJ ;
Zimran, A .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (18) :2835-2843